Posted by Michael Wonder on 18 Nov 2025
Lupron Depot new strength receives Health Canada approval for the treatment of advanced prostate cancer
17 November 2025 - AbbVie announced today that a new 6 month 45 mg Lupron Depot (leuprolide acetate for extended release injectable suspension) strength has received Health Canada approval for the treatment of advanced prostate cancer.
Lupron Depot is now available in four dosing options: 7.5 mg (1 month), 22.5 mg (3 month), 30 mg (4 month) and 45 mg (6 month).
Lupron Depot was initially approved by Health Canada for advanced prostate cancer in 1989, providing 36 years of proven clinical use in Canada.
